Lilly 51641[N-(2-chlorophenoxyethyl)-cyclopropylamine] a selective inhibitor of Type A monoamine oxidase (MAO) activity, was given for 9 to 73 days to eight inpatients with different primary psychiatric diagnoses. After two weeks treatment at daily doses exceeding 200 mg by mouth, this patient group exhibited greater than 90% mean reduction in plasma amine oxidase activity, which persisted for three weeks following discontinuation of the drug. Consistent reductions in platelet MAO were also noted, although the magnitude was less than 25% and such reductions persisted for less than one week following discontinuation of active drug. All 7 patients receiving active drug for longer than two weeks or at daily doses exceeding 200 mg by mouth exhibited significant and substantial mean increases in ratings of agitation or mania. The three female patients seemed especially vulnerable to such excitation during the week prior to their menses. The only two patients with primary affective illness-one patient with unipolar and one with bipolar depression-had the lowest baseline platelet MAO activities, and showed dramatic antidepressant responses on the drug. In contrast, two schizo-affective patients showed either decreased agitation or increased depression during treatment with daily doses of 50 to 150 mg orally. The one schizophrenic and one schizo-affective patient with highest baseline platelet MAO were the only two patients who exhibited an increase in psychosis on active drug. Gross fragmentation of nocturnal sleep and daytime drowsiness were seen in all patients. The circadian rhythm in body temperature decreased in amplitude on the drug. All patients developed postural hypotension on this drug-a side effect which was managed adequately by dosage reduction and temporary bedrest.
|Original language||English (US)|
|Number of pages||11|
|Journal||Communications In Psychopharmacology|
|State||Published - Dec 1 1978|
ASJC Scopus subject areas